Integrated control of hypertension by olmesartan medoxomil and hydrochlorothiazide and rationale for combination

Henry A PunziTrinity Hypertension and Metabolic Research Institute, Punzi Medical Center, Carrollton, TX, USA; Department of Family and Community Medicine, UT Southwestern Medical Center, Dallas, TX, USAAbstract: Hypertension affects nearly one-third of all individuals in the US, yet one-half of all...

Full description

Bibliographic Details
Main Author: Punzi HA
Format: Article
Language:English
Published: Dove Medical Press 2011-12-01
Series:Integrated Blood Pressure Control
Online Access:http://www.dovepress.com/integrated-control-of-hypertension-by-olmesartan-medoxomil-and-hydroch-a8806
id doaj-37893eeafbe846a1b48410f90377e7a9
record_format Article
spelling doaj-37893eeafbe846a1b48410f90377e7a92020-11-24T23:25:19ZengDove Medical PressIntegrated Blood Pressure Control1178-71042011-12-012011default7383Integrated control of hypertension by olmesartan medoxomil and hydrochlorothiazide and rationale for combinationPunzi HAHenry A PunziTrinity Hypertension and Metabolic Research Institute, Punzi Medical Center, Carrollton, TX, USA; Department of Family and Community Medicine, UT Southwestern Medical Center, Dallas, TX, USAAbstract: Hypertension affects nearly one-third of all individuals in the US, yet one-half of all treated patients achieve blood pressure (BP) controlled to recommended goals. The percentage of patients with uncontrolled BP is likely to be much higher when considering the number of patients who are not even aware of their hypertensive state. Elevated BP is associated with increased risks of cardiovascular events and end-organ damage. Antihypertensive monotherapy is not always sufficient to achieve BP goals, and thus more aggressive treatment regimens need to be considered. Antihypertensive combination therapy, which may improve tolerability, offers the benefit of targeting different mechanisms of action. Numerous outcomes studies support the use of a renin–angiotensin system inhibitor as a first-line choice in antihypertensive therapy. This review discusses the benefits of combination therapy with the angiotensin type II receptor blocker olmesartan medoxomil (OM) paired with the thiazide diuretic hydrochlorothiazide (HCTZ). The pharmacokinetic properties of OM will be reviewed in addition to efficacy studies that support OM + HCTZ combination therapy over other possible antihypertensive combinations. Finally, a rationale for choosing HCTZ over another diuretic, chlorthalidone, will also be discussed based on pharmacokinetic differences, clinical concerns, and trends in use.Keywords: antihypertensives, blood pressure, combination therapy, HCTZhttp://www.dovepress.com/integrated-control-of-hypertension-by-olmesartan-medoxomil-and-hydroch-a8806
collection DOAJ
language English
format Article
sources DOAJ
author Punzi HA
spellingShingle Punzi HA
Integrated control of hypertension by olmesartan medoxomil and hydrochlorothiazide and rationale for combination
Integrated Blood Pressure Control
author_facet Punzi HA
author_sort Punzi HA
title Integrated control of hypertension by olmesartan medoxomil and hydrochlorothiazide and rationale for combination
title_short Integrated control of hypertension by olmesartan medoxomil and hydrochlorothiazide and rationale for combination
title_full Integrated control of hypertension by olmesartan medoxomil and hydrochlorothiazide and rationale for combination
title_fullStr Integrated control of hypertension by olmesartan medoxomil and hydrochlorothiazide and rationale for combination
title_full_unstemmed Integrated control of hypertension by olmesartan medoxomil and hydrochlorothiazide and rationale for combination
title_sort integrated control of hypertension by olmesartan medoxomil and hydrochlorothiazide and rationale for combination
publisher Dove Medical Press
series Integrated Blood Pressure Control
issn 1178-7104
publishDate 2011-12-01
description Henry A PunziTrinity Hypertension and Metabolic Research Institute, Punzi Medical Center, Carrollton, TX, USA; Department of Family and Community Medicine, UT Southwestern Medical Center, Dallas, TX, USAAbstract: Hypertension affects nearly one-third of all individuals in the US, yet one-half of all treated patients achieve blood pressure (BP) controlled to recommended goals. The percentage of patients with uncontrolled BP is likely to be much higher when considering the number of patients who are not even aware of their hypertensive state. Elevated BP is associated with increased risks of cardiovascular events and end-organ damage. Antihypertensive monotherapy is not always sufficient to achieve BP goals, and thus more aggressive treatment regimens need to be considered. Antihypertensive combination therapy, which may improve tolerability, offers the benefit of targeting different mechanisms of action. Numerous outcomes studies support the use of a renin–angiotensin system inhibitor as a first-line choice in antihypertensive therapy. This review discusses the benefits of combination therapy with the angiotensin type II receptor blocker olmesartan medoxomil (OM) paired with the thiazide diuretic hydrochlorothiazide (HCTZ). The pharmacokinetic properties of OM will be reviewed in addition to efficacy studies that support OM + HCTZ combination therapy over other possible antihypertensive combinations. Finally, a rationale for choosing HCTZ over another diuretic, chlorthalidone, will also be discussed based on pharmacokinetic differences, clinical concerns, and trends in use.Keywords: antihypertensives, blood pressure, combination therapy, HCTZ
url http://www.dovepress.com/integrated-control-of-hypertension-by-olmesartan-medoxomil-and-hydroch-a8806
work_keys_str_mv AT punziha integratedcontrolofhypertensionbyolmesartanmedoxomilandhydrochlorothiazideandrationaleforcombination
_version_ 1725558217038102528